&Partners’s Allogene Therapeutics ALLO Stock Holding History

&Partners’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.2K	Buy	15,000 +5,000	+50%	+$11K	﹤0.01%	2500
2026 Q1	$24.4K	Buy	+10,000	New	+$20K	﹤0.01%	2377

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

&Partners's ALLO Position: Q2 2026 in Review

&Partners increased its Allogene Therapeutics (ALLO) stake by 50% in Q2 2026, buying an estimated $11K and bringing the position to 15,000 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2500.

&Partners first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

&Partners held 15,000 shares of Allogene Therapeutics worth $31.2K as of Q2 2026.
&Partners bought 5,000 Allogene Therapeutics shares in Q2 2026, an estimated $11K.
Allogene Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2500 holding.
&Partners first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.